Skip to main content
. 2021 Jun 7;12:3400. doi: 10.1038/s41467-021-23620-z

Fig. 1. The concentrations of plasma NfL for different diagnostic and controls groups in the KCL and Lund cohorts.

Fig. 1

Plasma neurofilament light (NfL) in different diagnostic groups; KCL (A n  =  805) and Lund (B n  =  1464) cohorts. For each plot, the horizontal bar shows the median, and the upper and lower boundaries show the 25th and 75th percentiles, respectively. Source data are provided as a Source Data file. KCL Cohort—AD    Alzheimer’s disease (n = 102), ALS   amyotrophic lateral sclerosis (n = 50), CU Aβ− cognitively unimpaired without Aβ pathology (n = 130), CU Aβ+ cognitively unimpaired with Aβ pathology (n = 28), CBS/PSP   corticobasal syndrome and progressive supranuclear palsy (n = 19), depression (n = 37), DS    Down syndrome (n = 29), DSAD   Down syndrome Alzheimer’s disease (n = 12), EOAD   early-onset Alzheimer’s disease (n = 59), FTD   frontotemporal dementia (n = 54), MCI Aβ− mild cognitive impairment without Aβ pathology (n = 55), MCI Aβ+ mild cognitive impairment with Aβ pathology (n = 31), PD   Parkinson’s disease (n = 140), PDD/DLB   Parkinson’s disease dementia and dementia with Lewy bodies (n = 59). Lund Cohort—AD   Alzheimer’s disease (n = 134), CU Aβ− cognitively unimpaired without Aβ pathology (n = 273), CU Aβ+ cognitively unimpaired with Aβ pathology (n = 103), CBS/PSP   corticobasal syndrome and progressive supranuclear palsy (n = 24), EOAD   early-onset Alzheimer’s disease (n = 23), FTD   frontotemporal dementia (n = 150), MCI Aβ− mild cognitive impairment without Aβ pathology (n = 115), MCI Aβ+ mild cognitive impairment with Aβ pathology (n = 165), MSA   multiple system atrophy (n = 29), PD    Parkinson’s disease (n = 171), PDD/DLB   Parkinson’s disease dementia and dementia with Lewy bodies (n = 46), SCD Aβ− subjective cognitive decline without Aβ pathology (n = 134), SCD Aβ+ subjective cognitive decline with Aβ pathology (n = 75), VaD vascular dementia (n = 22).